MDMA-assisted therapy for PTSD: What the research involves
MDMA-assisted therapy is being researched as a possible treatment for post-traumatic stress disorder, including for people whose symptoms have not improved with established treatments. This Insight looks at what the therapy involves, why it is being studied under controlled conditions, and why the clinical process is very different from taking MDMA outside a research setting.
On this page
What is being studied?
MDMA-assisted therapy combines pharmaceutical-grade MDMA with structured psychological therapy. The drug is not being studied as a standalone treatment for PTSD.
In a clinical setting, MDMA is given as part of a planned course of care that includes assessment, preparation, supervised treatment sessions and follow-up therapy.
Researchers are studying whether the effects of MDMA may help some people engage with traumatic memories in a way that makes psychological therapy more manageable.
The research is focused particularly on people with persistent or treatment-resistant PTSD, where established approaches have not provided enough improvement. Trials are designed to test both safety and effectiveness before any wider use could be considered.
What does the treatment involve?
MDMA-assisted therapy is delivered as a structured process rather than a single treatment session. Before taking part, people are assessed to establish whether the therapy is suitable for them, including consideration of physical health, mental health and other factors that may affect safety.
Preparation takes place before MDMA is given, allowing time to establish the therapeutic relationship and explain what the treatment may involve. The MDMA session itself takes place in a controlled clinical setting and can last several hours, with trained therapists present throughout.
Follow-up sessions are then used to talk through and make sense of what emerged during the supervised session. This preparation, monitoring and follow-up form part of the therapy being studied, rather than sitting separately from the use of MDMA.
Why are there safeguards?
MDMA-assisted therapy is being studied within tightly controlled clinical trials because the treatment can affect both physical and mental health, and it is not suitable for everyone.
Before taking part, people are screened against medical and psychological eligibility criteria. Current research excludes some people where there may be additional safety concerns, including certain cardiovascular conditions. Some medicines can also affect eligibility and may need to be reviewed as part of the assessment process.
The supervised setting is also part of the safeguard. MDMA can temporarily raise heart rate and blood pressure and may cause anxiety, restlessness or other physical effects. Trained clinicians are present throughout the dosing session so that changes can be monitored and any problems managed.
Psychological screening matters for the same reason. The treatment involves working with traumatic memories while under the effects of MDMA, so researchers need to consider whether taking part is appropriate for each individual.
These safeguards are part of what the trials are designed to test: who may benefit, who may face additional risk, and whether the treatment can be delivered safely within a clinical setting.
Clinical MDMA and street ecstasy
The MDMA used in clinical research is pharmaceutical-grade and given at a controlled dose within a supervised treatment programme. Street ecstasy is different because its contents and strength cannot be known with the same certainty.
Outside a clinical trial there is also no assessment to establish whether MDMA is suitable for the person taking it, no controlled setting and no trained clinicians monitoring what happens. The preparation and follow-up therapy that form part of MDMA-assisted treatment are absent as well.
This distinction matters because the research is examining MDMA as one part of a structured psychological therapy. Taking ecstasy independently does not reproduce the treatment being studied in clinical trials.
Where the research stands
MDMA-assisted therapy remains investigational in the UK. Current work is focused on clinical trials designed to understand how effective the treatment may be, who it may be suitable for and how it can be delivered safely.
Researchers at the University of Cambridge are developing further work in this area, including a trial involving veterans and others with treatment-resistant PTSD. The research is being carried out within a controlled clinical framework and remains subject to the usual research and regulatory requirements.
Research is also continuing in the United States, including studies involving veterans. Although interest and investment in psychedelic-assisted treatments have increased, MDMA-assisted therapy is still being studied rather than offered as routine PTSD treatment.
Any wider use in the UK would depend on the results of further trials and the regulatory processes that follow.
Finding support
Support for veterans is available through established NHS, statutory and voluntary-sector services. The VALOUR campaign website provides information about veteran support and routes to services across the UK.